Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

62944

registered interest
date	19/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for what reasons NICE has not recommended the treatment of abiraterone for use on the NHS; if he will place in the Library all correspondence NICE has received on the issue from (a) patient groups and (b) clinicians; and if he will make a statement.
tabling member constituency	Chelmsford
tabling member printed	Mr Simon Burns
uin	201499
answer	answer is ministerial correction date of answer 24/06/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) published technology appraisal guidance in June 2012 which recommends abiraterone (Zytiga) in its licensed indication for the treatment of castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen, subject to a patient access scheme agreed between the Department and the drug's manufacturer.</p><p> </p><p>NICE is currently appraising abiraterone for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy and has not yet published final guidance for the National Health Service. We understand that NICE has recently consulted on its draft guidance for this indication, which can be found at:</p><p> </p><p>http://guidance.nice.org.uk/TAG/434/Consultation/Latest</p><p> </p><p>NHS commissioners are legally required to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>In the absence of NICE technology appraisal guidance it is for the relevant NHS commissioner to make funding decisions based on an assessment of the available evidence. The NHS Constitution states that patients have the right to expect local decisions on the funding of drugs and treatments 'to be made rationally following a proper consideration of the evidence'.</p><p> </p><p>We understand that abiraterone as a first-line treatment is available through the Cancer Drugs Fund to NHS patients in England who could benefit from it.</p><p> </p><p>We are unable to provide copies of the correspondence requested in the time available and this information will be placed in the Library in due course.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 24/06/2014 14:09:43 answering member 1439 label Biography information for Norman Lamb
tabling member	46 label Biography information for Sir Simon Burns

63454

registered interest
date	18/06/2014
answering body	HM Treasury
answering dept id	14
answering dept short name	Treasury
answering dept sort name	CaTreasury
hansard heading	Long-term Economic Plan
house id	1
legislature	25259 pref label House of Commons
question text	To ask Mr Chancellor of the Exchequer, what recent assessment he has made of the effectiveness of his long-term economic plan.
tabling member constituency	Chelmsford
tabling member printed	Mr Simon Burns
uin	904415
answer	answer is ministerial correction date of answer 24/06/2014 answer text <p>The government's long-term economic plan is working, and the UK is expected to grow faster than any other G7 country this year. Inflation is below target, the deficit has been reduced by over a third since 2009-10, and employment is at record levels. But the job is not yet done and the biggest risk now to the recovery would be abandoning the plan that is delivering a brighter economic future.</p> answering member constituency Loughborough answering member printed Nicky Morgan question first answered 24/06/2014 14:25:53 answering member 4027 label Biography information for Baroness Morgan of Cotes
tabling member	46 label Biography information for Sir Simon Burns